In a hearing like this, I can't go looking at the papers every two minutes. Whatever the exact number is, the message I'm trying to convey is that there has been a gradual decline in compliance. This means that we're not the ones who are changing. A gradual decline in compliance means that we have to hire more staff to do the investigations. At the end of the investigations, we don't always find that the price is excessive, but we find that there's something that has triggered it. When we render decisions in our hearings, the pharmaceutical manufacturer is not always the loser.
The thing you have to take away from this is that there's a voluntary compliance. The industry has paid a lot of money back to the federal government, because they have realized that they were outside the guidelines. This amount of money, since the start of this board some 20 years ago, is more than $70 million.